QNCX · Categories · Form 4

QNCX - SEC Form 4 insider transactions

Quince Therapeutics Inc. (QNCX) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for QNCX

• 98d
  SEC Form 4 filed by CEO and CMO Thye Dirk

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 98d
  SEC Form 4 filed by President Ryan Charles S.

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 98d
  SEC Form 4 filed by CBO, COO & CCO Hannah Brendan

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 100d
  SEC Form 4 filed by Director Senner Christopher J.

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 100d
  SEC Form 4 filed by Director Mcloughlin Margaret

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 100d
  SEC Form 4 filed by Director Lamond David

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 100d
  SEC Form 4 filed by Director Bray June

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 123d
  Director Benatti Luca sold $173,500 worth of shares (50,000 units at $3.47), decreasing direct ownership by 56% to 39,179 units (SEC Form 4)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 123d
  Director Benatti Luca acquired 8,918 shares, increasing direct ownership by 11% to 89,179 units (SEC Form 4)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 140d
  CEO and CMO Thye Dirk gifted 739,885 shares and received a gift of 739,885 shares, decreasing direct ownership by 74% to 255,000 units (SEC Form 4)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 145d
  CBO, COO & CCO Hannah Brendan exercised 27,551 shares at a strike of $0.91, increasing direct ownership by 8% to 361,827 units (SEC Form 4)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 313d
  CBO, COO & CCO Hannah Brendan was granted 37,736 shares, increasing direct ownership by 13% to 334,276 units (SEC Form 4)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 313d
  President Ryan Charles S. was granted 7,548 shares, increasing direct ownership by 6% to 130,009 units (SEC Form 4)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 313d
  CEO and CMO Thye Dirk was granted 150,944 shares, increasing direct ownership by 18% to 994,885 units (SEC Form 4)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 329d
  SEC Form 4 filed by Director Ryan Una S

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 329d
  SEC Form 4 filed by Director Benatti Luca

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 329d
  SEC Form 4 filed by Director Senner Christopher J.

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 329d
  SEC Form 4 filed by Director Lamond David

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 329d
  SEC Form 4 filed by Director Mcloughlin Margaret

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 329d
  SEC Form 4 filed by Director Patni Rajiv

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 329d
  SEC Form 4 filed by Director Bray June

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 444d
  SEC Form 4 filed by CEO AND CHIEF MEDICAL OFFICER Thye Dirk

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 444d
  SEC Form 4 filed by PRESIDENT Ryan Charles S.

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 444d
  SEC Form 4 filed by CBO, COO and CCO Hannah Brendan

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 478d
  SEC Form 4 filed by Director Mcloughlin Margaret

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 478d
  SEC Form 4 filed by Director Bray June

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 478d
  SEC Form 4 filed by Director Lamond David

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 478d
  SEC Form 4 filed by Director Senner Christopher J.

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 693d
  SEC Form 4 filed by Lamond David

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 693d
  SEC Form 4 filed by Mcloughlin Margaret

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 693d
  SEC Form 4 filed by Ryan Una S

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 693d
  SEC Form 4 filed by Senner Christopher J.

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 693d
  SEC Form 4 filed by Bray June

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 693d
  SEC Form 4 filed by Benatti Luca

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 693d
  SEC Form 4 filed by Patni Rajiv

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 695d
  Hannah Brendan exercised 56,061 shares at a strike of $0.55, increasing direct ownership by 28% to 257,616 units (SEC Form 4)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 806d
  SEC Form 4 filed by Patni Rajiv

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 819d
  SEC Form 4 filed by Ryan Charles S.

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 819d
  SEC Form 4 filed by Hannah Brendan

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 819d
  SEC Form 4 filed by Thye Dirk

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 835d
  Thye Dirk exercised 240,530 shares at a strike of $0.79, increasing direct ownership by 54% to 689,441 units (SEC Form 4)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 920d
  SEC Form 4 filed by Benatti Luca

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 920d
  SEC Form 4 filed by Janhofer Guenter

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 968d
  SEC Form 4 filed by Ryan Charles S.

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 974d
  SEC Form 4: Lamond David bought $107,898 worth of shares (82,052 units at $1.31)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 988d
  SEC Form 4: Lamond David bought $325,737 worth of shares (250,000 units at $1.30)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 994d
  SEC Form 4: Thye Dirk bought $110,880 worth of shares (88,000 units at $1.26), increasing direct ownership by 24% to 448,911 units

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 996d
  SEC Form 4: Thye Dirk bought $99,200 worth of shares (80,000 units at $1.24), increasing direct ownership by 28% to 360,911 units

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 996d
  SEC Form 4: Hannah Brendan bought $87,550 worth of shares (71,762 units at $1.22), increasing direct ownership by 55% to 201,555 units

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 996d
  SEC Form 4: Mcloughlin Margaret bought $9,840 worth of shares (8,000 units at $1.23)

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 1071d
  SEC Form 4 filed by Senner Christopher J.

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 1071d
  SEC Form 4 filed by Ryan Una S

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 1071d
  SEC Form 4 filed by Mcloughlin Margaret

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 1071d
  SEC Form 4 filed by Lamond David

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 1071d
  SEC Form 4 filed by Bray June

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 1184d
  SEC Form 4 filed by Thye Dirk

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 1184d
  SEC Form 4 filed by Smith Karen L.

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 1184d
  SEC Form 4 filed by Monohon Ted

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
• 1184d
  SEC Form 4 filed by Hannah Brendan

  4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

Other QNCX categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends